Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib
暂无分享,去创建一个
Yeon-Hee Park | S. Im | K. Jung | Kyunghee Park | J. Sohn | J. Kim | K. Lee | Yaewon Yang | Ji-Yeon Kim | ji-Yeon Kim